Purple Biotech (PPBT) Accumulated Expenses (2018 - 2021)

Purple Biotech (PPBT) has disclosed Accumulated Expenses for 4 consecutive years, with $1.5 million as the latest value for Q4 2021.

  • On a quarterly basis, Accumulated Expenses rose 73.52% to $1.5 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.5 million, a 73.52% increase, with the full-year FY2021 number at $1.5 million, up 73.52% from a year prior.
  • Accumulated Expenses was $1.5 million for Q4 2021 at Purple Biotech, up from $880000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.5 million in Q4 2021 to a low of $255000.0 in Q4 2019.
  • A 4-year average of $878500.0 and a median of $866000.0 in 2018 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 70.07% in 2019, then surged 245.1% in 2020.
  • Purple Biotech's Accumulated Expenses stood at $852000.0 in 2018, then crashed by 70.07% to $255000.0 in 2019, then soared by 245.1% to $880000.0 in 2020, then skyrocketed by 73.52% to $1.5 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Accumulated Expenses are $1.5 million (Q4 2021), $880000.0 (Q4 2020), and $255000.0 (Q4 2019).